Therapeutic Potential of Fluoxetine in Neurological Disorders
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
The selective serotonin reuptake inhibitor (SSRI) fluoxetine, which is registered for a variety of psychiatric disorders, has been found to stimulate the cAMP‐responsive element binding protein (CREB), increase the production of brain‐derived neurotrophic factor (BNDF) and the neurotrophic peptide S100β, enhance glycogenolysis in astrocytes, block voltage‐gated calcium and sodium channels, and decrease the conductance of mitochondrial voltage‐dependent anion channels (VDACs). These mechanisms of actions suggest that fluoxetine may also have potential for the treatment of a number of neurological disorders. We performed a Pubmed search to review what is known about possible therapeutic effects of fluoxetine in animal models and patients with neurological disorders. Beneficial effects of fluoxetine have been noted in animal models of stroke, multiple sclerosis, and epilepsy. Fluoxetine was reported to improve neurological manifestations in patients with Alzheimer's disease, stroke, Huntington's disease, multiple sclerosis, traumatic brain injury, and epilepsy. Clinical studies so far were small and often poorly designed. Results were inconclusive and contradictory. However, the available preclinical data justify further clinical trials to determine the therapeutic potential of fluoxetine in neurological disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Shimizu, S., Narita, M., Tsujimoto, Y., & Tsujimoto, Y. (1999) · Nature · doi:10.1038/20959 · Cited by 2,178 · cited 1×
“Inhibition of the VDAC by fluoxetine protected against staurosporine-induced apoptotic cell death in human U-937 cells (Shimizu et al. 1999; Nahon et al. 2005).”
BackgroundFunction and regulation of CREB family transcription factors in the nervous system
Lonze, B. E., & Ginty, D. D. (2002) · Neuron · doi:10.1016/s0896-6273(02)00828-0 · Cited by 2,127
Apoptosis in neurodegenerative disorders
Mattson, M. P. (2000) · Nature Reviews Molecular Cell Biology · doi:10.1038/35040009 · Cited by 1,605
Mitochondria take center stage in aging and neurodegeneration
Beal, M. F. (2005) · Annals of Neurology · doi:10.1002/ana.20624 · Cited by 957
Glycogen regulation and functional role in mouse white matter
Brown, A. M., Tekkök, S. B., & Ransom, B. R. (2003) · The Journal of Physiology · doi:10.1113/jphysiol.2003.042416 · Cited by 243
Tekkök, S. B., Brown, A. M., Westenbroek, R., Pellerin, L., & Ransom, B. R. (2005) · Journal of Neuroscience Research · doi:10.1002/jnr.20573 · Cited by 224
Boggio, P. S., Fregni, F., Bermpohl, F., Mansur, C. G., Rosa, M., Rumi, D. O., Barbosa, E. R., Odebrecht Rosa, M., Pascual‐Leone, A., Rigonatti, S. P., et al. (2005) · Movement Disorders · doi:10.1002/mds.20508 · Cited by 216
MAP Kinase Activation by Fluoxetine and Its Relation to Gene Expression in Cultured Rat Astrocytes
Mercier, G., Lennon, A. M., Renouf, B., Dessouroux, A., Ramaugé, M., Courtin, F., & Pierre, M. (2004) · Journal of Molecular Neuroscience · doi:10.1385/jmn:24:2:207 · Cited by 176 · cited 2×
“Fluoxetine elevates BDNF levels in the rat brain (Mercier et al. 2004), and enhances the production of S100β in astrocytes (Haring et al.”
BackgroundNahon, E., Israelson, A., Abu-Hamad, S., & Shoshan-Barmatz, V. (2005) · FEBS Letters · doi:10.1016/j.febslet.2005.08.020 · Cited by 101 · cited 2×
“Inhibition of the VDAC by fluoxetine protected against staurosporine-induced apoptotic cell death in human U-937 cells (Shimizu et al. 1999; Nahon et al. 2005).”
BackgroundResponse of Emotional Unawareness After Stroke to Antidepressant Treatment
Spalletta, G., Ripa, A., Bria, P., Caltagirone, C., & Robinson, R. G. (2006) · The American Journal of Geriatric Psychiatry · doi:10.1097/01.jgp.0000194647.72654.a1 · Cited by 37 · cited 1×
“A significant increase of MMSE after 8 weeks of treatment in the 32 patients without alexithymia was noticed (Spalletta et al. 2006).”
Background
Cited by
Jiang, M., Wang, J., Fu, J., Du, L., Jeong, H., West, T., Xiang, L., Peng, Q., Hou, Z., Cai, H., et al. (2012) · Nature Medicine · doi:10.1038/nm.2558 · Cited by 345
Reversal of hippocampal neuronal maturation by serotonergic antidepressants
Kobayashi, K., Ikeda, Y., Sakai, A., Yamasaki, N., Haneda, E., Miyakawa, T., & Suzuki, H. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0912690107 · Cited by 212
Aureli, A., Del Beato, T., Sebastiani, P., Marimpietri, A., Melillo, C. V., Sechi, E., & Di Loreto, S. (2010) · International Journal of Immunopathology and Pharmacology · doi:10.1177/039463201002300323 · Cited by 36
Metadata
- Authors
- Mostert, J. P., Koch, M. W., Heerings, M., Heersema, D. J., & De Keyser, J.
- Venue
- CNS Neuroscience & Therapeutics
- Publisher
- Wiley
- Published
- 2008-05-14
- Volume
- 14
- Issue
- 2
- Pages
- 153-164
- ISSN
- 1755-5930 (ISSN-L)
- 1755-5949
- OpenAlex
- W2009623771
- Cited by
- 101
- References
- 10
- FWCI
- 2.98
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Therapeutic Potential of Fluoxetine in Neurological Disorders. https://app.cochat.ai/papers/10.1111/j.1527-3458.2008.00040.x
- The paper
- Mostert, J. P., Koch, M. W., Heerings, M., Heersema, D. J., & De Keyser, J. (2008). Therapeutic Potential of Fluoxetine in Neurological Disorders. CNS Neuroscience & Therapeutics. https://doi.org/10.1111/j.1527-3458.2008.00040.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.